CV Sciences
CV Sciences, Inc. (OTC: CVSI) is a life science and consumer wellness company focused on the development and commercialization of hemp-derived cannabidiol (CBD) products for human and pet health and wellness applications. According to its website at cvsciences.com, the company operates two business segments: a consumer products segment that develops and markets hemp-derived CBD dietary supplements, topicals, and pet products under the PlusCBD brand through natural health retail, drug store, online, and direct-to-consumer distribution channels; and a drug development segment that is pursuing the development of pharmaceutical-grade CBD-based drug candidates for specific medical indications under FDA regulatory oversight. This dual-track strategy enables CV Sciences to generate near-term consumer product revenue while pursuing the longer-term opportunity of developing approved pharmaceutical CBD products.
CV Sciences' consumer products segment, described at cvsciences.com, markets its PlusCBD brand hemp-derived CBD products through a broad retail distribution network that includes natural health retailers such as Whole Foods Market and Natural Grocers, drug store chains including CVS and Rite Aid, and online retail platforms including Amazon and the company's own direct-to-consumer website. PlusCBD's product portfolio spans full-spectrum hemp oil tinctures, softgels and capsules, topical creams and balms, and pet CBD products, providing consumers with a comprehensive range of CBD delivery formats across multiple product categories. CV Sciences maintains rigorous quality standards for its PlusCBD products, including third-party testing and Certificates of Analysis that verify cannabinoid content and the absence of pesticides, heavy metals, and other contaminants.
CV Sciences' pharmaceutical development segment is advancing a CBD-based drug development program targeting cannabidiol's potential therapeutic applications in obesity, binge eating disorder, and other metabolic conditions where preclinical and early clinical data suggest the potential for meaningful therapeutic benefit. According to cvsciences.com, the pharmaceutical program leverages the company's extensive knowledge of cannabidiol chemistry, pharmacology, and clinical research to develop proprietary drug formulations with the stability, bioavailability, and dosing precision required for regulated pharmaceutical applications. CV Sciences' combination of an established consumer CBD brand generating near-term revenue and a pharmaceutical CBD development program targeting longer-term drug approval creates a diversified value proposition for investors interested in the hemp CBD industry.